P&G Could Be Last Suitor Standing For Pfizer's Consumer Health Business
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
A spin-off still is an option for Pfizer, as is continuing to operate the unit as it currently does. But P&G's apparent interest and dearth of other OTC business buyers changes the outlook for both companies.
You may also be interested in...
GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes
Reckitt and GSK withdraw from negotiating on potential deals for with Pfizer's consumer business, leaving slim chances Pfizer will receive an acceptable offer from other drug firms mentioned as potential suitors for the business, which it has valued at around $20bn. A spin-off could move to the fore.
P&G Extends Gum Repair Toothpaste Line As It Trims Production Footprint
P&G says harmful plaque bacteria below the gum line evades "even the most the diligent brushers." The firm plans in 2020 to move manufacturing of hair, oral and personal care products from Iowa to a facility in West Virginia.
P&G Goes Native In Acquisition That Aligns With Peltz' Recommendations
P&G purchase of Native deodorants likely is approved by activist investor and potential board member Nelson Peltz, who has pushed the firm to invest in small and local brands as well as natural products. It could be first in a series of tuck-in deals to help the firm compete with e-commerce start-ups.